Reports Q3 revenue $33.986M, consensus $31.1M. “We delivered another strong performance with third quarter net sales of $34.0 million, up 33% year-over-year, and $4.6 million in net income,” said Niagen Bioscience (NAGE) CEO Rob Fried. “Our results reflected the continued execution across the business, with sustained sales growth, margin expansion, and disciplined cost management. The progress across both scientific leadership and commercial reach reinforces our confidence in the long-term fundamentals of our leadership in the NAD+ category.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir
- Niagen CFO Pamir says ‘very much focused’ on profitability
- Niagen growing fast, financial health a priority, CFO tells The Fly
- Niagen CFO expects Parkinson’s trial results in early 2026
- Niagen Bioscience CFO says ‘very conservative’ in how business run